Polygenic risk score analysis of pathologically confirmed Alzheimer's disease by Escott-Price, Valentina et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/101628/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Escott-Price, Valentina, Myers, Amanda J, Huentelman, Matt and Hardy, John 2017. Polygenic risk
score analysis of pathologically confirmed alzheimer's disease. Annals of Neurology 82 (2) , pp.
311-314. 10.1002/ana.24999 file 
Publishers page: http://dx.doi.org/10.1002/ana.24999 <http://dx.doi.org/10.1002/ana.24999>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Genetic prediction in pathological Alzheimer’s  Escott-Price et al. 
 1 
PolygeŶic Risk Score AŶalysis of 
Pathologically CoŶfirŵed Alzheiŵer’s 
Disease 
Valentina Escott-Price PhD1, Amanda J. Myers PhD2, Matt Huentelman PhD3 and John 
Hardy PhD4*. 
 
1. Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for 
Neuropsychiatric Genetics and Genomics, Cardiff University, UK. 
2. Department of Psychiatry & Behavioral Sciences, Programs in Neuroscience and 
Human Genetics and Genomics and Center on Aging, Miller School of Medicine, 
University of Miami, Miami, FL USA 
3. Neurogenomics Division, The Translational Genomics Research Institute (TGen), 
Phoenix, AZ 85004 
4. Department of Molecular Neuroscience and Reta Lilla Weston Laboratories, 
Institute of Neurology, London, UK. 
 
address for correspondence at j.hardy@ucl.ac.uk 
 
Keywords Alzheimer’s disease, genetics, pathology 
 
Title 111 characters 
Running title 47 characters 
Abstract 76 words 
Introduction 257 words 
Discussion 311 words 
Word count 1373 
 
  
Genetic prediction in pathological Alzheimer’s  Escott-Price et al. 
 2 
Abstract 
Previous estimates of the utility of polygenic risk score analysis for the prediction of Alzheimer’s disease have given Area Under the Curve estimates of <80%.  However, 
these have been based on the genetic analysis of clinical case control series.  Here we 
apply the same analytic approaches to a pathological case control series and show a 
predictive AUC of 84%.  We suggest that this analysis has clinical utility and that there is 
limited room for further improvement using genetic data. 
Introduction 
Polygenic risk score (PRS) analysis enhances the predictability of the diagnosis of Alzheimer’s disease ȋADȌ over the use of just the apolipoprotein E locus (1).  In a recent 
PRS analysis, we showed that the area under the curve (AUC) in the recent genome wide 
association study (GWAS), was 0.79 (1).  However, the study samples in these cohorts 
were largely comprised of clinical cases of AD, and the diagnostic accuracy of these is 
not perfect as recent clinical trial failures have highlighted (2). In addition, the majority 
of controls which are used in GWAS, are sampled from a general population and are 
often underaged to develop AD.  This diagnostic uncertainty has also been 
demonstrated by the observation of c9orf72 expansions (a locus causing 
frontotemporal dementia) within some of the clinical AD cohorts used in the generation 
of the GWAS and AD sequencing data (3). 
Having a better understanding of the diagnostic utility of PRS is of importance for two 
reasons: first, because it enables the accurate assessment of how much risk for disease 
there is still left to be found and this is important in setting research goals, and second, 
because this type of analysis could be used in the refinement of inclusion criteria for 
clinical trials and eventually, in clinical health care recommendations. 
We have previously reported a GWAS in clinically characterized and 
neuropathologically confirmed samples of AD and matched controls (4): in this analysis, 
we apply PRS to these pathological data to determine whether some of the ǲmissing heritabilityǳ of AD is due to clinical misdiagnosis. 
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Methods 
The sample characteristics of the dataset used in this study were the same as in our 
original analysis. This project was declared IRB exempt (Medstar Project #.2003-118) 
under the Code of Federal Regulations, 45 CFR, 46.  Eight cases and eight controls had 
corrupted data files and were omitted (4).  This left 1011 cases and 583 controls.  The 
total number of imputed single nucleotide polymorphisms (SNPs) was 36,481,940. The 
number of SNPs with Info score above 0.8 was 11,016,052.  From these, the number of 
SNPs with MAF>=0.01 was 7,868,100 and these were used in the analysis. Association 
analysis was performed for each SNP using logistic regression analysis as implemented 
in snptest (5). 
We performed predictive modelling using polygenic score based upon SNPs with p-
value cut-off p=10-4, 10-3, Ͳ.Ͳͳ, Ͳ,Ͳͷ, … Ͳ.ͷ as in (7) as predictor variables. These sets of 
SNPs are capturing APOE and index GWAS SNPs (7) either directly or via their proxies. For prediction modelling we converted imputed ǲdosageǳ genotypes in our data to ǲmost probable genotypeǳ with probability over ͻͲ%. The individual polygenic risk 
scores were generated as sum of the risk alleles weighted by effect sizes as in the 
International Genomics of Alzheimer's Project (IGAP) study (7), then were further 
adjusted for first 10 principal components and standardized.  The models were fitted 
using the above mentioned individual polygenic risk scores and predicting AD/control 
status in our study. This is the most powerful way of testing the prediction ability of the 
strongest genetic predictors to date: however our study was part of the IGAP study (7) 
(~3% overlap) and therefore the results will be marginally overfitted.  We accounted 
for this overfitting in our analysis as below. 
Since summary statistics for the IGAP (7) data excluding our sample was not available 
to us, we estimated the effect of possible bias using simulations.  For that we first 
simulated a sample of 17008 cases and 37154 controls, matching the IGAP stage-I study, 
for a typical SNP with minor allele frequencies=0.2 and effect size of odds ratio 
(OR)=1.05. This OR matches the average effect size for IGAP pruned SNPs with 
association p-value≤0.5, mean(BIGAP)=0.05, mean(SEIGAP)=0.035; 
ORIGAP=exponential(0.05)=1.05. Then we randomly removed 1101 cases and 583 
controls (matching our study size) and recalculated the association effect size 1000 
times de novo. The ǲremoval-based-simulatedǳ effect sizes for a single typical SNP were 
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found to be normally distributed with mean BSIM=0.05 (SDSIM=0.004) (not shown). 
Assuming that the removed sample is a random subset of cases and controls, the 
expected distribution of the IGAP pruned SNPs effect sizes should have the same mean 
but slightly increased standard error:  
SEIGAP-ADJ=SEIGAP*sqrt(N)/sqrt(N-No), 
where N is the IGAP sample size, No is the overlap sample size. In particular, we can 
roughly expect the mean(SEIGAP)ADJ=0.035/sqrt(0.97)=0.0355, where 0.035 is the 
mean(SEIGAP) of the effect size for IGAP pruned SNPs with association p-value≤0.5. 
To adjust prediction modelling for overlapping samples, we ran further simulations 
where the effect sizes for each SNP in the IGAP study were simulated as b~N(BIGAP, 
sd=0.12*SEIGAP), where BIGAP is the beta-coefficient and SEIGAP is the standard error for 
that SNP in the IGAP study. The sd=0.12*SEIGAP was chosen empirically to allow for both 
the variability due to IGAP B-coefficient estimate and due to random subsample 
removal. As a rough example, multiplying the mean(SEIGAP)ADJ by 0.12 results in a 
standard deviation, which is approximately matching the ǲremoval-based-simulatedǳ 
SDSIM: 0.12*mean(SEIGAP)ADJ =0.12*0.0355 ≈ 0.004= SDSIM. Thus, in each simulation step, 
each SNP in IGAP had a simulated effect size and p-value corresponding to this effect 
size. Then the SNPs were reselected, repruned and the polygenic scores recalculated. 
The prediction accuracy of the simulated PRS was calculated at each simulation (N 
simulations =1000) and mean of simulated AUC for SNPs with p≤Ͳ.ͷ was reported and 
is discussed below. 
Results 
The primary results (QQ-plot and Manhattan plot) were consistent with our previous 
analysis of these data (4). There were no genome-wide significant hits apart from APOE 
locus.  
We compared the results of our analysis with 21 index genome-wide significant SNPs 
identified in the IGAP (7) study (see Table 1). Sixty three percent of IGAP GWAS index 
SNPs (14 out of 22) show larger effects in our dataset compared to the original report 
(7), of which 5 have significantly larger effect sizes (see the last column of Table 1), 
including the two SNPs tagging the APOE status. 
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The results of predictive modelling are presented in Table 2.  Training on the whole 
IGAP the prediction accuracy AUC reaches 86% (Figure 1) when all SNPs with p≤0.5 are 
included in the model, However, as discussed above there is an element of overfitting in 
this analysis as our data was part of the IGAP analysis.  Accounting for this possible 
inflation using simulation (see Methods), the prediction accuracy is 84% (95%CI 82-
86%). 
Discussion 
These data systematically confirm, in the context of genome wide data, our results 
examining the APOE locus (4): genetic prediction is better in the context of autopsy 
confirmed cases and controls.  This has implications for our view of how much genetic 
variability remains to be found: in an earlier analysis, we estimated that the theoretical 
maximal genetic variance to be found would generate an AUC of 82% (95% confidence 
interval 78%-85%) (8).  The figure now identified, based on the genome wide analysis 
of a pathological cohort is 84% (95% confidence interval 82-86%). Thus the theoretical 
and assessed the figures for risk prediction accuracy overlap and both are larger than 
the AUC of 0.75 assessed using clinical cohorts (1).  There is thus further evidence that 
polygenic risk profiling captures the SNP-heritability very well with regards to common 
variation in AD, although of course, heritability estimates (8) were constructed on 
clinical diagnoses of AD so strict comparisons are hazardous. This does not imply that 
there are no genetic findings of very rare variants (f<0.1%) still to be made, although 
the increasing predictability of genetic findings (9-12) and the fact that most new 
findings relate to already identified pathways implies that research may be better 
focused on the targeted sequencing of established pathways, bioinformatic analyses of 
multi-omics data sets, and cell biology rather than on large scale genome wide 
sequencing projects in unrelated sporadic AD individuals.  These data also illustrate that 
there is a degree of misdiagnosis in the clinical AD series (3), and even more so in 
population based controls.  
A final implication of these data is that genome wide genotyping and PRS based analytic 
strategies are reasonably effective at predicting those who will develop disease. They 
also suggest that this predictive utility is unlikely to improve much more. This strategy 
may therefore now be useful for designing clinical trials and eventually in clinical 
practice.  
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Table 1. Comparison of neuropathologically confirmed data analysis with IGAP genome-wide significant index SNPs (Lambert et al 2013) 
 
SNP CHR BP A1 A2 
IGAP Corneveaux 
P_test.DIFF BETA SE OR P BETA SE OR P 
rs6656401 1 207692049 A G 0.167 0.017 1.181 5.69E-24 0.251 0.096 1.285 0.0093 0.805 
rs4663105 2 127891427 A C -0.184 0.017 0.832 1.00E-26 0.026 0.085 1.026 0.763 0.992 
rs6733839 2 127892810 T C 0.197 0.014 1.217 6.94E-44 NA NA NA NA NA 
rs35349669 2 234068476 T C 0.076 0.014 1.078 3.17E-08 0.076 0.080 0.927 0.3445 0.501 
rs190982 5 88223420 G A -0.076 0.014 0.927 3.23E-08 -0.119 0.082 0.888 0.1456 0.302 
rs10948363 6 47487762 G A 0.095 0.015 1.100 5.20E-11 0.121 0.088 0.886 0.1664 0.614 
rs2718058 7 37841534 G A -0.077 0.013 0.926 4.76E-09 0.025 0.079 0.975 0.7499 0.900 
rs1476679 7 100004446 C T -0.089 0.014 0.915 5.58E-10 -0.188 0.082 0.829 0.0224 0.119 
rs11771145 7 143110762 A G -0.102 0.014 0.903 1.12E-13 -0.171 0.087 1.186 0.0503 0.218 
rs28834970 8 27195121 C T 0.100 0.013 1.105 7.37E-14 0.009 0.080 0.991 0.9079 0.133 
rs9331896 8 27467686 C T -0.146 0.014 0.864 2.77E-25 -0.128 0.079 0.880 0.1057 0.586 
rs10838725 11 47557871 C T 0.079 0.014 1.082 1.12E-08 0.018 0.084 0.982 0.8273 0.239 
rs983392 11 59923508 G A -0.108 0.013 0.898 
6.14E-
16 -0.290 0.078 1.336 0.0002 0.011 
rs10792832 11 85867875 A G -0.140 0.013 0.869 9.32E-26 -0.173 0.079 0.842 0.0288 0.342 
rs11218343 11 121435587 C T -0.262 0.034 0.770 9.73E-15 -0.461 0.187 1.586 0.0136 0.147 
rs17125944 14 53400629 C T 0.132 0.023 1.141 7.95E-09 -0.012 0.130 1.012 0.9282 0.137 
rs10498633 14 92926952 T G -0.095 0.016 0.910 
5.54E-
09 -0.271 0.088 1.311 0.0022 0.025 
rs8093731 18 29088958 T C -0.316 0.081 0.729 0.000105 0.229 0.409 0.795 0.5753 0.904 
rs4147929 19 1063443 A G 0.143 0.018 1.154 1.06E-15 0.112 0.097 1.119 0.2489 0.378 
rs429358 
(e4) 19 45411941 T C -1.350 0.027 0.259 0 -1.748 0.115 0.174 
8.2x10-
52 0.0004 
rs7412 (e4) 19 45412079 T C -0.387 0.040 0.679 
1.23E-
22 -1.031 0.154 2.804 
1.9x10-
11 2.46E-05 
rs3865444 19 51727962 A C -0.067 0.014 0.935 
2.97E-
06 -0.223 0.083 1.250 0.0073 0.032 
rs7274581 20 55018260 C T -0.132 0.024 0.876 2.46E-08 -0.235 0.140 1.264 0.0934 0.235 
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Table 2. Predictive accuracy for 1101 clinically characterized and neuropathologically confirmed samples of AD and 583 controls. The PRS’ were constructed 
using independent SNPs associated with AD in IGAP at different significance levels (MODEL column). Numbers of SNPs participating in the predictive model are 
given in column N SNPs. 
MODEL Effect SE p NSNPs Sensitivity Specificity AUC AUC.L95 AUC.U95 
1.00E-04 0.666 0.060 5.21E-29 299 0.617 0.617 0.676 0.649 0.703 
0.001 0.981 0.067 1.23E-48 1184 0.686 0.686 0.741 0.716 0.766 
0.01 1.385 0.078 1.14E-69 7030 0.734 0.734 0.807 0.786 0.829 
0.05 1.740 0.092 2.37E-79 29017 0.770 0.770 0.847 0.827 0.867 
0.1 1.813 0.094 2.59E-82 53329 0.770 0.770 0.853 0.834 0.873 
0.2 1.861 0.096 8.24E-84 96791 0.775 0.775 0.858 0.839 0.878 
0.3 1.899 0.097 3.23E-85 135642 0.789 0.789 0.863 0.843 0.882 
0.4 1.931 0.098 1.32E-85 171672 0.785 0.786 0.865 0.846 0.884 
0.5 1.943 0.099 8.22E-86 205068 0.790 0.791 0.866 0.847 0.886 
 
